A news report on the “Genetic Demonstration Center for High-Rise Tumor and Genetic Diseases†project in Shanghai recently brought benefits to the gene sequencing sector. Data show that the sector rose 2.68% yesterday, the entire sector is full of red, and one of the shares of Wuyuan Pharmaceuticals has a daily limit.
Zhongjiao Securities analyst Cheng Jiaoyi believes that this breakthrough will be conducive to the large-scale commercial promotion of the three-generation sequencer, and the clinical application in the sequencing field is expected to further differentiate. Sequencing, as the basic link of precision medical care , will drive the entire industry forward. The entire precision medical sector has resurfaced.
Gene Testing Demonstration Center will be launched in Shanghai
Genetic testing refers to the technique of detecting DNA by blood, body fluids or cells. At present, more than 1,000 diseases can be diagnosed by genetic testing technology, and the most widely used is the detection of neonatal hereditary diseases and prevention of birth defects.
Some insiders believe that the completion of the high-incidence tumor and genetic disease genetic testing demonstration center will help improve the prevention and treatment of major diseases such as genetic diseases and tumors.
In addition, the recent international journal PeerJ published online research by Ma Zhanshan, a researcher at the Kunming Institute of Zoology, Chinese Academy of Sciences, and Dr. Ye Chengyu from the University of Maryland, USA. The cooperation in gene sequencing has once again made an important breakthrough. The new algorithm reduces the error rate of three generations of sequencing to less than 0.5%.
Gene testing sector white horse stocks are favored
From the performance point of view, the data show that the first quarter of the genetic testing sector's net profit growth of 18, accounting for nearly 60% of the total, of which, the two quarters of Kangzhi Pharmaceutical, Zixin Pharmaceutical's performance increased over the same period 100%.
Wei Wei, an analyst at Shanghai Securities, believes that gene sequencing is the foundation of the entire precision medicine industry, and it is also a relatively mature field in the development of precision medicine. It is better in disease prevention, screening, diagnosis and individualized treatment. Application prospects.
Precision Medical Related Fund
M(I(K%5D)1.png)
Source: Eastern Fortune Choice data, Galaxy Securities, deadline: 2016-06-22
From the initial stoppage of the domestic policy, to the gradual opening of the pilot and the strengthening of supervision, the industry has been guided to develop in a healthy and orderly manner. The warming of the policy has also guaranteed the rapid development of genetic sequencing and even the entire precision medical treatment.
Wei Wei said that he will continue to be optimistic about the future development of precision medicine. Due to the high elasticity of the sector, specific event drivers may have a greater impact on the market performance of the sector.
From the perspective of specific investment directions, Cheng Jiaoyi believes that precision medical care, as a long-term growth-determined and unrelenting investment theme, has better investment opportunities in the short-term risk appetite. In the long run, the pharmaceutical sub-sectors are subject to policy. The impact of fluctuations, the industry changes significantly, it is recommended to configure the performance growth determination, low valuation and growth of the enterprise.
Yang Yun, an analyst at Zheshang Securities, also said that he is optimistic about the layout of A-share listed companies in the field of gene therapy. It is recommended to focus on the layout of listed companies in gene therapy, including cooperation, investment and independent research, as well as the company's clinical progress.
In terms of individual stocks, Shanxi Securities analyst Zhang Xu suggested focusing on leading companies such as Daan Gene, Anke Bio, and Dean Diagnostics. Cheng Jiaoyi suggested focusing on Liezhu Group, Beilu Pharmaceutical, and Daan Gene.
As a professional manufacturer of plant extracts, Insen biotech can supply lots of plant extracts and customize hundreds of proportional extract according to customers' needs, such as 4:1, 10:1, 20:1, 50:1 and others. These plant extracts are widely used in food, beverage and healthcare capsules or tablets. If you have any needs about any plant extracts, please contact Insen freely, and welcome to visit our factory.
Other Extracts,Astragalus Extract,Propolis Extract Powder,Water Soluble Glabridin
Hunan Insen Biotech Co., Ltd , https://www.insenhealth.com